Printer Friendly

ONASCO BIOTECHNOLOGIES DEVELOPS FIVE NEW VACCINES

 ONASCO BIOTECHNOLOGIES DEVELOPS FIVE NEW VACCINES
 HOUSTON, June 26 /PRNewswire/ -- ONASCO Biotechnologies, Inc.


today announced the development and manufacture of five new synthetic vaccines. These vaccines, prepared for research purposes only, include: 1) Poliovirus vaccine; 2) Human T-Lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) vaccine; 3) Spumavirus vaccine; 4) Type D retrovirus vaccine; and 5) A vaccine against most known retroviruses (RETROVAX), except HIV-1 and HIV-2. Extensive efficacy testing will be required for FDA approval and no assurance can be given as to the efficacy of these products nor to FDA approval.
 Recent theories of potential contamination of the monkey kidney cells, which are used to make poliovirus vaccines in the United States, prompted ONASCO to develop a totally synthetic poliovirus vaccine. The estimated U.S. market for poliovirus vaccines is $100 million per year. ONASCO hopes to capture a significant portion of this market upon successful completion of efficacy testing and FDA approval.
 ONASCO decided to manufacture small quantities of totally synthetic vaccines to other human and monkey retroviruses, besides HIV-1 and HIV-2, which include: 1) The human T-lymphotropic retrovirus types 1 and 2 (HTLV-1 and HTLV-2), which have been associated with certain diseases and are endemic in Japan; 2) The spumavirus (foamy virus), which has been isolated from both humans and monkeys; 3) The type D retrovirus, which causes most of the simian AIDS (SAIDS) in captive monkeys and has recently been isolated from a human with AIDS; and 4) a vaccine against many known retroviruses (RETROVAX), which includes HTLV-1, HTLV-2, spumavirus, and type D retroviruses. The company estimates that a multi-billion dollar market exists for these products worldwide, but is quick to point out that extensive efficacy testing must be done as well as FDA approval received before these vaccines are made available to the public. No assurance can be given that these products will prove to be effective or that FDA approval will be granted.
 ONASCO Biotechnologies, Inc. is a wholly owned subsidiary of ONASCO Companies, Inc., a publicly held corporation traded Over-The-Counter (OTC) on the NASD electronic bulletin board system (OBIO).
 -0- 6/26/92
 /CONTACT: Dr. Robert Bohannon of ONASCO Biotechnologies, 713-498-0779 or (fax) 713-933-0922/
 (OBIO) CO: ONASCO Biotechnologies Inc. ST: Texas IN: MTC SU: PDT


TS -- NY041 -- 4226 06/26/92 12:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 26, 1992
Words:383
Previous Article:FIRST FEDERAL SAVINGS BANK OF NEW SMYRNA ANNOUNCES DIVIDEND
Next Article:ULTRAMAR ANNOUNCES INITIAL PUBLIC OFFERING
Topics:


Related Articles
STRESSGEN AWARDED FEDERAL R & D GRANT AIMED AT STRESS PROTEIN-BASED THERAPEUTICS
AVAX Technologies Receives Orphan Drug Status for Its M-Vax Cancer Vaccine.
AVAX Technologies Extends Findings of Experimental Cancer Vaccine O-Vax(TM).
AVAX Technologies' M-Vax(TM) Cancer Vaccine Extends Five-Year Overall Survival In Patients With Lymph Node Metastatic Melanoma.
Integrated BioPharma Announces Appointment of Geoffrey Schild as Chief Scientific Officer; Internationally Known Virologist to Aid Firm's Pioneering...
Integrated BioPharma, Inc to Develop Flu Vaccine Using Its Proprietary Technology.
Integrated BioPharma, Inc. Announces New Appointment to Its Scientific Advisory Board.
Integrated BioPharma Participating in 'Innovations in Mitigating BioThreats' Conference.
Integrated BioPharma Announces the Appointment of General Hill as a Director of InB: Biotechnologies, Inc.
Carrington receives European patent for stabilization of proteins and peptides.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters